Key Points
- Patricia Carr, Jazz's chief accounting officer, sold 1,287 shares on March 9 at an average price of $182.94 for $235,444, leaving her with 6,512 shares (~$1.19M) and marking about a 16.5% reduction; she also sold 1,253 and 1,117 shares on Feb 26–27, bringing total insider sales to 3,657 shares in late Feb–early Mar.
- Jazz beat expectations in the latest quarter with EPS of $6.64 vs. $6.49 and revenue of $1.20B (up 8.1% year-over-year), though the company reported a negative net margin (-8.35%) and modest ROE (6.87%).
- Analysts are broadly positive: the consensus rating is "Moderate Buy" with an average target of $214.38 (13 Buys, 2 Holds, 1 Sell), and several firms have recently raised price targets (e.g., Wells Fargo to $250, Morgan Stanley to $226).
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Get Free Report) CAO Patricia Carr sold 1,287 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $182.94, for a total value of $235,443.78. Following the sale, the chief accounting officer directly owned 6,512 shares in the company, valued at approximately $1,191,305.28. This trade represents a 16.50% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Patricia Carr also recently made the following trade(s):
- On Friday, February 27th, Patricia Carr sold 1,117 shares of Jazz Pharmaceuticals stock. The stock was sold at an average price of $190.91, for a total value of $213,246.47.
- On Thursday, February 26th, Patricia Carr sold 1,253 shares of Jazz Pharmaceuticals stock. The shares were sold at an average price of $194.11, for a total value of $243,219.83.
Jazz Pharmaceuticals Stock Up 1.9%
Shares of Jazz Pharmaceuticals stock opened at $185.40 on Tuesday. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.86 and a quick ratio of 1.67. Jazz Pharmaceuticals PLC has a 1-year low of $95.49 and a 1-year high of $198.00. The business's fifty day moving average price is $171.41 and its two-hundred day moving average price is $154.78. The company has a market capitalization of $11.41 billion, a P/E ratio of -31.06, a PEG ratio of 0.33 and a beta of 0.22.
Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its quarterly earnings results on Tuesday, February 24th. The specialty pharmaceutical company reported $6.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.49 by $0.15. Jazz Pharmaceuticals had a positive return on equity of 6.87% and a negative net margin of 8.35%.The company had revenue of $1.20 billion during the quarter, compared to analysts' expectations of $1.17 billion. During the same quarter in the prior year, the business posted $6.51 earnings per share. The company's revenue for the quarter was up 8.1% compared to the same quarter last year. As a group, research analysts forecast that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.
Institutional Trading of Jazz Pharmaceuticals
A number of hedge funds have recently modified their holdings of the business. Royal Bank of Canada raised its position in Jazz Pharmaceuticals by 96.5% during the first quarter. Royal Bank of Canada now owns 67,614 shares of the specialty pharmaceutical company's stock valued at $8,394,000 after buying an additional 33,210 shares during the period. Goldman Sachs Group Inc. increased its holdings in shares of Jazz Pharmaceuticals by 147.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 351,609 shares of the specialty pharmaceutical company's stock valued at $43,652,000 after purchasing an additional 209,667 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Jazz Pharmaceuticals by 4.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 197,174 shares of the specialty pharmaceutical company's stock worth $24,479,000 after purchasing an additional 7,954 shares in the last quarter. Focus Partners Wealth boosted its holdings in shares of Jazz Pharmaceuticals by 3.4% during the first quarter. Focus Partners Wealth now owns 4,623 shares of the specialty pharmaceutical company's stock worth $574,000 after purchasing an additional 154 shares during the period. Finally, Geneos Wealth Management Inc. boosted its holdings in shares of Jazz Pharmaceuticals by 57.6% during the first quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company's stock worth $47,000 after purchasing an additional 137 shares during the period. Hedge funds and other institutional investors own 89.14% of the company's stock.
Analysts Set New Price Targets
A number of research firms have commented on JAZZ. Piper Sandler restated an "overweight" rating and set a $219.00 price target (up from $147.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, December 10th. Morgan Stanley increased their price objective on shares of Jazz Pharmaceuticals from $225.00 to $226.00 and gave the company an "overweight" rating in a report on Wednesday, February 25th. Weiss Ratings reiterated a "sell (d+)" rating on shares of Jazz Pharmaceuticals in a research note on Monday, December 29th. Wells Fargo & Company boosted their target price on Jazz Pharmaceuticals from $235.00 to $250.00 and gave the stock an "overweight" rating in a report on Wednesday, February 25th. Finally, TD Cowen restated a "buy" rating on shares of Jazz Pharmaceuticals in a research report on Thursday, January 29th. Thirteen equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $214.38.
Check Out Our Latest Report on Jazz Pharmaceuticals
About Jazz Pharmaceuticals
(
Get Free Report)
Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company's research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz's product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.
Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
